P16 and P14ARF are two tumor suppressors encoded by the locus ink4a-arf which is frequently deleted in human tumors. Recent experiments performed with mouse embryonic ®broblasts have shown that P14ARF is an upstream regulator of the P53 pathway. This raises the question as to whether in human tumors the loss of p14arf and mutation of p53 are mutually exclusive events which segregate with genetic alterations at other loci. To examine this question we performed a multigenic analysis on 29 gliomas. We analysed p53 and p14arf in relation with ®ve other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26. Our study shows for the ®rst time that p53 mutations and p14arf deletions appear mutually exclusive in human glioblastoma, suggesting that they may be functionally redundant in glioma tumorigenesis. The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV), either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%). These tumors further showed MDM2 overexpression (9.1%), egfr oncogene ampli®cation/egfr overexpression (50%), pten mutations (27.3%) and loss of heterozygosity (LOH) at the chromosomal regions 10q23.3 (86.4%) and 10q25-26 (100%). These alterations did not segregate with p53 mutations or p14arf deletions, while p14arf and cdkn2a were always deleted. Oncogene (2000) 19, 3816 ± 3822.
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The gene encoding P14ARF is an alternative reading frame of the locus ink4a-arf located on chromosome 9p21 and encoding also the cell cycle suppressor P16 (Duro et al., 1995; Kamijo et al., 1997; Mao et al., 1995; Stone et al., 1995) . Both P16 and P14ARF are inhibitors of cell cycle progression but act in two dierent ways: P16 is an upstream regulator of the retinoblastoma protein (PRb) pathway and inhibits cyclin dependent kinases 4 and 6 (Kamb et al., 1994) . P14ARF increases P53 stability by sequestering MDM2 in the nucleolus, thus preventing MDM2 mediated ubiquitin ligase activity on P53 (Honda and Yasuda, 1999; Pomerantz et al., 1998; Zhang and Xiong, 1999) .
Furthermore, studies on mouse embryonic ®bro-blasts indicate that P53 levels can be augmented by activation of an oncogene in the cell and that this is mediated by P14ARF (de Stanchina et al., 1998; Zhang and Xiong, 1999; Zindy et al., 1998) . Since in human tumors the loci ink4a-arf and p53 are frequently disrupted, it raises the question whether these are mutually exclusive events and whether they segregate with similar genetic alterations at other loci.
Astrocytomas are a very diverse and complex group of neoplasms that provide the genetic heterogeneity necessary to address these questions. Genetic analyses in gliomas have shown that both the PRb and P53 pathways are frequently disrupted, either by direct mutations in the genes encoding these two proteins, or by aecting other genes encoding proteins that are part of these two pathways such as MDM2, P14ARF or P16. Other genes such as pten and egfr are also frequently altered in gliomas, indicating that they have an important role in the genesis of these tumors. Moreover, frequent deletions on the chromosomal region 10q25-26 (deleted in 90% of tumors), distal to the pten gene, suggest the existence of other genes, which may be involved in gliomagenesis. Two potential tumor suppressor genes have been identi®ed in this region (dmbt1 and H-neu), but their role in tumorigenesis is not yet clear (Mollenhauer et al., 1997; Nakamura et al., 1998) .
To evaluate the relevance of the new ®ndings in mouse cells, showing that P14ARF is part of the P53 pathway to human tumorigenesis, we made a multigenic analysis (p53, cdkn2a, p14arf, mdm2, pten, the 10q23.3 and 10q25-26 loci, and egfr) on 29 gliomas (20 grade IV, two grade III and seven grade II) (Table 1) .
Gross deletions and alterations of the cdkn2a locus have been found with variable frequencies (30 ± 60%) in glioblastomas (He et al., 1994; Hegi et al., 1997; Jen et al., 1994; Nishikawa et al., 1995; Schmidt et al., 1994) , but these studies did not speci®cally examine the status of the p14arf gene. Here, we have analysed the status of p14arf and cdkn2a for microdeletions by dierential PCR, using primers speci®c for exon 1b, unique for p14arf, and for exon 3, that is speci®c for GBM=glioblastoma; AB=astroblastoma; A=astrocytoma; O=oligodendroglioma; E=ependymoma; OA=oligoastrocytoma. ink4a-arf: + retention of both alleles; 7 hemizygous deletion; HD homozygous deletion; (1) obtained borderline values between 7 and HD. p53 and pten genes. The position of the codon, the aminoacid substitution, the exon, the position of the mutation on the cDNA sequence and the nucleotide substitution are indicated sequentially. MDM2: IHC=immunohistochemistry; ND=not determined; 7 less 1% cells positive; +1 ± 5% cells positive; ++ 5 ± 15% cells positive; f=focal. EGFR: EGFR trunc=truncated form of EGFR (EGFRvIII deleted exons 2 ± 7); amp=ampli®cation; IHC=immunohistochemistry; ND=not determined; + ampli®ed/overexpressed; 7 not ampli®ed/overexpressed. Chromosome 10q: we previously reported part of these data (Maier et al., 1997 (Maier et al., , 1998 ; LOH=loss of heterozygosity; MI=microsatellite instability; + retention of both alleles; 7 hemizygous deletion. Survival and Operation age/sex: ND=not determined; m=male; f=female. Tumor location: BF=bifrontal; RT=right temporal; RP=right parietal; LO=left occipital; LF=left frontal; RF=right frontal; LP=left parietal; LT=left temporal Figure 1 Allelic dosage analysis for the p14arf (A) and cdkn2a (B) genes using dierential PCR. DNA fragments were ampli®ed in exon 1b of p14arf, exon 3 of cdkn2a and exon 2 of ifn-g using the primers described below. LN-Z308 is a glioblastoma cell line with an intact ink4a-arf locus that we used as positive control. LN-343 is a glioblastoma cell line with deleted ink4a-arf used as negative control. Due to the unequal ampli®cation eciency during the PCR reaction for the dierent genes analysed, the ratio of DNA fragment intensity in LN-Z308 between exon 1b or exon 3 and the internal control ifn-g was used to normalize the results in the tumor samples. In tumors BS7 and BS56 the ratio of DNA fragment intensity between exon 1b or exon 3 and the ifn-g was 70 ± 100% of the ratio found in LN-Z308, suggesting that there was no loss at this locus. The ratio in BS40 and BS50 was 50% of the one found in LN-Z308 and was interpreted as hemizygous deletion. LS971 and BS2 had a ratio less than 40% of the ratio found in LN-Z308 and were considered as homozygously deleted. Lymphocyte DNA of patient BS2 (B) has also been analysed with the same method and shows a ratio equal to 100% of the one found in LN-Z308, con®rming that the loss of ink4a-arf is a genetic event restricted to tumor cells. Method: DNA was extracted from paran embedded tissues as previously described (Maddalena et al., 1999) and used as a template in a PCR reaction with 30 cycles using an annealing temperature of 508C, as previously described (Frye et al., 1989) . Primers used were: p14arf exon 1b: ARF2F 5'-ctcgtgctgatgctactgag-3' and ARF2R 5'-aagtcgttgtaacccgaatg-3', p16 exon 3: p16ex3F 5'cgattgaaagaaccagagag-3' and p16ex3R 5'-atggacatttacggtagtgg-3'; ifn-g gene: INFGF2dF 5'-gcaggtcattcagatgtagcp53 and ink4a-arf alterations in human gliomas G Fulci et al p16. The allelic balance at these two exons was determined using the interferon-g (ifn-g) gene as an internal allele dosage standard (Frye et al., 1989) ( Figure 1A ,B). The results were con®rmed with the use of quantitative TaqMan PCR performed with¯uor-escent primers speci®c for exon 1b (unique for p14arf) and exon 1a (unique for p16) and using the gapdh gene as an internal allele dosage standard ( Figure 1C ). The data were also con®rmed by microsatellite analyses on chromosome 9p21 ( Figure 1D ) (Cairns et al., 1995) . In total, the two genes (p14arf and cdkn2a) were found homozygously deleted in 12 of 22 (54.5%) malignant gliomas (Table 1) . One high grade tumor (4.5%) and three low grade samples showed hemizygous loss. One malignant tumor showed borderline results between homozygous and hemizygous deletions (BS21). No exclusive loss of either cdkn2a or p14arf was found in these 29 tumors and sequencing of exon 1b in these tumors did not identify any point mutations (data not shown). p53 gene status was analysed using a functional assay in yeast that examines wild type (wt) or mutant status of P53 mRNA extracted from frozen tumors (Waridel et al., 1997) . In this assay tumor-derived p53 mRNA is reverse transcribed and the resulting cDNA is expressed in yeast. If the p53 cDNA encodes wt P53 the yeast are white, if it encodes mutant P53 the yeast are red. Plasmids containing mutated p53 cDNA extracted from red yeast were sequenced. The p53 gene was found mutated in eight out of 29 gliomas (27.6%) ( Table 1 and Figure 2A ), a frequency similar to that found in other studies (reviewed in Fulci et al., 1998; Kleihues et al., 1994) .
In six cases mutated p53 transcripts represented over 90% of tumor p53 mRNA (90% red colonies) suggesting homozygosity for the mutant allele. In two cases (BS7 and BS43) only about 50% of p53 transcripts were mutated, either due to tumor heterogeneity or retention of one wild type allele. Seven of these tumors had missense point mutations. All point mutations were situated in evolutionarily conserved and functionally important domains of the P53 protein (reviewed in Fulci et al., 1998) . One tumor (LS991) had a six base pairs (bp) insertion at codon 157, which occurs as a repetition of the sequence CCGCGC (Figure 2A) . This leads to a mutant P53 protein with in frame insertion of two amino acids. This mutant protein was transcriptionally inactive in yeast.
mdm2 ampli®cation was analysed by dierential PCR (Biernat et al., 1997a) . Ampli®cation of this gene was found in none of the tumors (data not shown). This con®rms that mdm2 gene ampli®cation is uncommon in human gliomas (Reifenberger et al., 1993) . Immunohistochemistry (IHC) showed overexpression in about 10 ± 15% of cells in two of 22 high grade gliomas (9.1%) and none in low grade gliomas (Table 1 and Figure 2B ), similar to previously published results (Biernat et al., 1997a; Hunter et al., 1995) . The lack of mdm2 gene ampli®cation within these tumors can be due to two reasons. On the one hand, the low percentage (10 ± 15%) of MDM2 overexpressing cells might be under the detection limit of our dierential PCR analysis for mdm2 ampli®cation. On the other hand, enhanced translation might also induce MDM2 overexpression (Landers et al., 1994; Biernat et al., 1997a) . Immunohistochemistry analysis for P53 performed on these two tumors has shown positive P53 staining only in tumor LS971 with 1 ± 3% of positive nuclei diusely distributed throughout the section. No positive or negative correlation between MDM2 and P53 staining was observed.
egfr gene dosage was analysed by dierential PCR using the ifn-g gene as an internal gene dosage control ( Figure 3A ) (Frye et al., 1989) . Gene ampli®cation was seen in eight out of 22 high grade gliomas (36.4%) ( Table 1) . EGFR overexpression was determined by immunohistochemistry as described previously (Sure et al., 1997) ( Figure 3B ). As positive controls we used paran sections from gliomas with known ampli®ca-tion of the egfr gene as determined by Southern 3' and INFG2RdR 5'-agagcacaaacagaggatga-3'. (C) Allelic dosage analysis for the p14arf and cdkn2a-genes using the TaqMan ABI PRISM 7700 Sequence Detection System (Perkin Elmer). Left panel indicates the results obtained with a lymphocyte DNA sample used as positive control. The threshold level of DNA ampli®cation is joined after the same number of PCR cycles (22.5) for the gapdh gene and for exon 1b and exon 1a of ink4a-arf locus. The right panel indicates the results obtained in tumor LS971. The threshold level of DNA ampli®cation is joined after 24 cycles of PCR for gapdh gene (light green, yellow and red curves) and after about 27.5 cycles for exon 1b and 1a of ink4a-arf locus (all the other curves). Method: The number of DNA ampli®cation cycles needed to join the threshold level is evaluated for exon 1b and exon 1a and normalized with the number of cycles needed for gapdh gene (used as an internal standard). The results obtained using the DNA extracted from the tumors were compared to the ones obtained with lymphocyte DNA (positive control). The PCR reactions were performed with the following primers labeled with thē uorescent dye FAM: gapdh exon 6 5'-aatgggactgaggctcccac and 5'-ttatgggaaagccagtcccc; exon 1b 5'-tgatgctactgaggagccagc and 5'-agggcctttcctacctggtc; exon 1a 5'-cccaacgcaccgaatagttac and 5'-attccaattcccctgcaaact. Gene speci®c¯uorescent oligomeric probes were: gapdh 5'-atccaagactggctcctccctgctg (sense), exon 1b 5'-tctagggcagcagccgcttcctaga (sense) and exon 1a 5'ccacctggatcggcctccgg (antisense). (D) Allelic dosage for the ink4a-arf locus analysing the heterozygosity of dierent markers on chromosome 9p21. Left: schematic representation of chromosome 9p21 with the DNA markers analysed and the position of the ink4a-arf locus. Right: scans of the most representative DNA markers ampli®ed by PCR and size-separated by capillary electrophoresis and analysed using the fragment analysis program of ABI prism (Perkin Elmer). Loss of heterozygosity for each marker (LOH) was determined by examining whether there was any loss of the peaks representing each allele between constitutive blood DNA (B) and tumor DNA (T) from the same patient. BS40 and BS50 show LOH at all four markers shown. BS56 shows retention of both alleles at all four markers shown. Tumors with homozygous deletions are not shown but were determined following the criteria previously described (Cairns et al., 1995) . Presence (1,2) or absence (0) of alleles is indicated. Method: LOH analysis was performed as previously described (Maier et al., 1999) using the following¯uorescent labeled primers (Microsynth, Switzerland). The dye used to label the primers is indicated next to the primer: inf-a: forward 5'-tgcgcgttaagttaattggtt-3' (6FAM) and reverse 5'-gtaaggtggaaacccccact-3'; D9S1749: forward 5'-aggagagggtacgcttgcaa-3' (HEX) and reverse 5'-tacagggtgcgggtgcagataa-3'; D9S2136: forward 5'-attcaacgagtgggatgaag-3' (HEX) and reverse 5'-tccaggttgctgcaaatgcc-3'; D9S942: forward 5'-gcaagattccaaacagta-3' (6FAM) and reverse 5'-ctcatcctgcggaaaccatt-3'; D9S1748: forward 5'-cacctcagaagtcagtgagt-3' (TET) and reverse 5'-gtgcttgaaatacacctttcc-3'; D9S171: forward 5'-agctaagtgaacctcatctctgtct-3' (TET) and reverse 5'-accctagcactgatggtatagtct-3'. Hematoxylin and Eosin staining performed on sections microdissected just before and after the ones used for DNA extraction guaranteed the presence of at least 80% of tumoral material in the tissue analysed with the three methods described above analysis . Nine out of 22 tumors (41%) showed elevated expression of the protein (Table  1) . In seven of these cases overexpression of the protein was associated with egfr gene ampli®cation. One tumor (LS971), in addition, displayed expression of a truncated form of EGFR (deleted for the extracellular region encoded by exons 2 ± 7) in a portion of the tumor (data not shown). This was detected with an antibody directed against the mutant-speci®c epitope present in the truncated extracellular domain of mutant EGFR (NCL-EGFRT; Novocastra Laboratories Ltd). This EGFR alteration leads to a constitutively activated receptor which results in a growth advantage (Nishikawa et al., 1994) . As a positive control, we used paran embedded cells transduced with a retroviral vector expressing the exon 2 ± 7 deleted EGFR cDNA (Nishikawa et al., 1994) . No egfr gene ampli®cation and/or overexpression was seen in grade II or III tumors.
pten mutations and LOH analyses on chromosome 10q23.3 and 10q25-26 were performed as described (Maier et al., 1997 (Maier et al., , 1998 ). LOH at the 10q23.3 locus Figure 2 (A) p53 mutations detected in tumors BS7 (G ± A transversion at nucleotide 524), BS36 (G ± A 733, in the ®gure is shown the complementary strand), BS43 (G ± A 646, in the ®gure is shown the complementary strand), BS56 (A ± C 773, in the ®gure is shown the complementary strand) and LS991 (six base pairs insertion at nucleotide 470). Method: Mutant p53 was evidenced as previously described (Waridel et al., 1997) . Sequencing was performed by Microsynth (Balgach, Switzerland) using a Perkin Elmer ABI Prism 377 sequencer. (B) Overexpression of MDM2 in glioblastoma LS971. (a) Shows about 10% of tumor cells stained positively for MDM2, (b) shows the tumor stained only with the secondary antibody. Method: Immunohistochemistry for MDM2 was performed using an anti-MDM2 monoclonal antibody (clone IF2, Oncogene Science, Uniondale, NY, USA) as previously described (Biernat et al., 1997a) Figure 3 (A) Analysis for egfr gene ampli®cation using dierential PCR on blood (B) and tumor (T) DNA. Results of blood DNA samples show that PCR ampli®cation occurred at equal rates for the ifn-g and egfr gene fragments allowing for direct comparison of fragment intensities. Tumors BS2, BS7 and BS43 show the same ratio of ifn-g and egfr allele dosage in DNA extracted from lymphocytes and tumor, whereas samples BS56 and LS971 show an increased level of egfr in the tumor DNA compared to the lymphocyte DNA, suggesting gene ampli®cation in the latter two cases. Although poorly ampli®ed in the LS971 reaction, the ifn-g gene is clearly present in this tumor (see Figure  1A) . Method: DNA extractions and PCR reactions were performed as previously described (Maddalena et al., 1999; Frye et al., 1989) . (B) Overexpression of EGFR determined by immunohistochemistry. Strong focal expression is detected in tumor LS912 (a) but not in an adjacent section stained only with the secondary antibody (b). Method: Immunohistochemistry on EGFR was performed with a monoclonal antibody (NCL-EGFR; Novocastra Laboratories Ltd., Newcastle, UK) as previously described (Sure et al., 1997) was found in 19 out of 22 (86.4%) malignant gliomas (WHO grades III and IV) (Table 1) consistent with previous reports (Chiariello et al., 1998; Duerr et al., 1998; Maier et al., 1997 Maier et al., , 1998 Teng et al., 1997; Wang et al., 1997) and in six cases this was associated with mutations in the pten gene in the remaining allele (27.3%) (Table 1) (Maier et al., 1997 (Maier et al., , 1998 . No pten mutations were present in low grade tumors, although 42.8% presented LOH at the 10q23.3 locus. Loss of one allele at the 10q25-26 locus was found in 100% of 22 high grade tumors, similar to previous reports (Chiariello et al., 1998; Duerr et al., 1998; Maier et al., 1997 Maier et al., , 1998 Teng et al., 1997; Wang et al., 1997) . Five of seven (71.4%) grade 2 tumors analysed had also LOH at 10q25-26 (Maier et al., 1998) .
Pairwise comparison was performed for each genetic marker using Fisher's test. We found a signi®cant negative correlation between deletions at the ink4a-arf locus and p53 mutations in malignant gliomas (P50.01). Even though the ink4a-arf locus is related to both the P53 and the PRb pathways, the clear negative correlation existing between these two genetic events supports the view that in human glioblastomas loss of P14ARF represents an important alternative way to disrupt the P53 pathway of tumor suppression. In agreement with this interpretation, high grade tumors harboring p53 mutations presented no particular dierences in clinical history compared to the ones deleted for p14arf. The disruption of both the P53 and PRb pathways in glioblastomas has been frequently reported. In glioblastomas with mutated P53, PRb pathway alterations usually occur either by PRb mutations or by cdk4/6 ampli®cation (Biernat et al., 1997b; Ichimura et al., 2000) . We did not examine PRb and CDK4/6 status in this study. In glioblastomas with wt P53, PRb and P53 functions are frequently lost through either ink4a-arf loss or MDM2 overexpression. MDM2 is known to sequester and inactivate both P53 and PRB (Grossman et al., 1998; Oliner et al., 1993; Xiao et al., 1995) . The two tumors with wt P53 (LS971 and BS13) in which we found focal overexpression of MDM2 had also deleted ink4a-arf, suggesting that a combination of redundant mechanisms might have been selected for P53 and PRb inactivation in these tumors. All these ®ndings suggest that both the P53 and the PRb tumor suppressor pathways need to be disrupted for the development of malignant gliomas, yet this may occur at dierent stages during tumor development. In low grade astrocytomas degenerating into secondary glioblastomas p53 gene alteration is already present and the transition to higher grade requires loss of the PRb pathway (reviewed in Fueyo et al., 1998; von Deimling et al., 1995) . Progression to higher grade tumors then involves pRb gene mutation, loss of the cdkn2a gene or ampli®cation of the cdk4 or cdk6 genes to inactivate the PRb pathway (Biernat et al., 1997b; Costello et al., 1997; Meyer-Puttlitz et al., 1997) . This explains why some tumors such as LS946 have both P53 mutation and P14ARF loss. The sequence of events in primary glioblastomas cannot be determined since precursor lesions to these malignancies have not yet been clinically identi®ed. No correlation was found between pten mutations and loss of either p14arf or p53.
In conclusion, the P53 pathway is disrupted in 81.8% of malignant gliomas, either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%). No inverse correlation between p53 mutation and p14arf loss was observed in small cell lung cancer and contradictory results were obtained in non-small cell lung cancer (Gazzeri et al., 1998; Sanchez-Cespedes et al., 1999; Vonlanthen et al., 1998) . This might represent dierences in the mechanisms of tumorigenesis in lung and brain. An attractive hypothesis would be that the agents that provide selective pressure to mutate the P53 pathway are dierent in both tissues. In mouse models P14ARF was shown to mediate P53 induction following activation of an oncogene (de Stanchina et al., 1998; Zhang and Xiong, 1999; Zindy et al., 1998) . Therefore, an oncogenic switch in gliomagenesis might create a selective pressure to mutate either p14arf or p53. In some studies an association between cdkn2a deletion and egfr ampli®cation/EGFR overexpression was found Hegi et al., 1997) , although other not yet identi®ed oncogenes might also be involved. In contrast, in lung cancer the DNA damaging agents contained in tobacco smoke could create a selective pressure to mutate p53 but not p14arf, since P53 activation by DNA damage occurs independently of P14ARF (de Stanchina et al., 1998) . If this holds true, analysis of p14arf and p53 status in tumors might provide clues as to which type of cellular insult (oncogenic switch or DNA damage) occurs in dierent types of cancers.
In this study we show for the ®rst time an inverse correlation between p14arf and p53 gene alterations in glioblastoma. Clearly this observation needs to be con®rmed in larger tumor series. These preliminary data in human tumors support ®ndings in mice that p14arf loss or p53 mutation are alternative means by which a tumor can inactivate the P53 pathway.
